Rallybio Corporation

RLYB · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Revenue$212$212$212$38
% Growth0%0%457.9%
Cost of Goods Sold$0$0$0$30
Gross Profit$212$212$212$8
% Margin100%100%100%21.1%
R&D Expenses$4,143$6,074$5,725$7,355
G&A Expenses$2,994$4,195$4,157$4,261
SG&A Expenses$2,994$4,195$4,157$4,261
Sales & Mktg Exp.$0$0$0$0
Other Operating Expenses$0$0$0$0
Operating Expenses$7,137$10,269$9,882$11,616
Operating Income-$6,925-$10,057-$9,670-$11,608
% Margin-3,266.5%-4,743.9%-4,561.3%-30,547.4%
Other Income/Exp. Net$22,941$354$231$564
Pre-Tax Income$16,016-$9,703-$9,439-$11,044
Tax Expense$0$0$0$0
Net Income$16,016-$9,703-$9,439-$11,044
% Margin7,554.7%-4,576.9%-4,452.4%-29,063.2%
EPS0.36-0.22-0.21-0.25
% Growth263.6%-4.8%16%
EPS Diluted0.36-0.22-0.21-0.25
Weighted Avg Shares Out45,05944,84144,77544,661
Weighted Avg Shares Out Dil45,05944,84144,77544,661
Supplemental Information
Interest Income$462$523$644$811
Interest Expense$0$0$0$0
Depreciation & Amortization$35$26$28$30
EBITDA$16,051-$10,031-$9,642-$11,578
% Margin7,571.2%-4,731.6%-4,548.1%-30,468.4%